Manyoo A Agarwal1, Lohit Garg2, Carl J Lavie3, Guy L Reed4, Rami N Khouzam4. 1. Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. 2. Division of Cardiovascular Medicine, Department of Internal Medicine, Lehigh Valley Medical Center, Allentown, PA, USA. 3. Division of Cardiovascular Medicine, Department of Internal Medicine, John Ochsner Heart and Vascular Institute, New Orleans, LA, USA. 4. Department of Internal Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA.
Abstract
BACKGROUND: Patients with a family history of coronary artery disease (FHxCAD) are at increased risk for development of myocardial infarction (MI). However, the data on the influence of FHxCAD on in-hospital clinical outcomes post ST-segment myocardial infarction (STEMI) is limited. Hence, we evaluated the impact of FHxCAD on in-hospital clinical outcomes post STEMI in an unselected nationwide cohort. METHODS: Nationwide Inpatient Sample (NIS) database [2003-2011] was used to compare differences in all-cause in-hospital mortality and adverse clinical events (cardiogenic shock, acute cerebrovascular events and use of intra-aortic balloon pump) between patients with and without FHxCAD. RESULTS: A total of 2,123,492 STEMI admissions were identified, of which 7.4% (n=158,079) patients were with FHxCAD and 92.6% (n=1,965,413) were without FHxCAD. The FHxCAD group had lower in-hospital mortality [1.4% vs. 8.1%; adjusted odds ratio (OR): 0.42, 95% confidence interval (CI): 0.41-0.44; P<0.001] when compared with no-FHxCAD group. They underwent a significantly higher number of coronary interventions, and were less likely to develop cardiogenic shock, acute cerebrovascular events and to require intra-aortic balloon pump during hospitalization. CONCLUSIONS: This large sample size study demonstrates that STEMI patients with FHxCAD had lower in-hospital mortality and adverse clinical events in comparison to patients with no-FHxCAD. Further research is warranted to determine whether the superior outcomes in FHxCAD patients with STEMI are related to differences in strategies related to diet, exercise, use of medications or coronary interventions.
BACKGROUND: Patients with a family history of coronary artery disease (FHxCAD) are at increased risk for development of myocardial infarction (MI). However, the data on the influence of FHxCAD on in-hospital clinical outcomes post ST-segment myocardial infarction (STEMI) is limited. Hence, we evaluated the impact of FHxCAD on in-hospital clinical outcomes post STEMI in an unselected nationwide cohort. METHODS: Nationwide Inpatient Sample (NIS) database [2003-2011] was used to compare differences in all-cause in-hospital mortality and adverse clinical events (cardiogenic shock, acute cerebrovascular events and use of intra-aortic balloon pump) between patients with and without FHxCAD. RESULTS: A total of 2,123,492 STEMI admissions were identified, of which 7.4% (n=158,079) patients were with FHxCAD and 92.6% (n=1,965,413) were without FHxCAD. The FHxCAD group had lower in-hospital mortality [1.4% vs. 8.1%; adjusted odds ratio (OR): 0.42, 95% confidence interval (CI): 0.41-0.44; P<0.001] when compared with no-FHxCAD group. They underwent a significantly higher number of coronary interventions, and were less likely to develop cardiogenic shock, acute cerebrovascular events and to require intra-aortic balloon pump during hospitalization. CONCLUSIONS: This large sample size study demonstrates that STEMI patients with FHxCAD had lower in-hospital mortality and adverse clinical events in comparison to patients with no-FHxCAD. Further research is warranted to determine whether the superior outcomes in FHxCAD patients with STEMI are related to differences in strategies related to diet, exercise, use of medications or coronary interventions.
Authors: Ahmed Abdi-Ali; AbdelAziz Shaheen; Danielle Southern; Mei Zhang; Merril Knudtson; James White; Michelle Graham; Mathew T James; Stephen B Wilton Journal: Am J Cardiol Date: 2015-11-18 Impact factor: 2.778
Authors: John G Canto; Catarina I Kiefe; William J Rogers; Eric D Peterson; Paul D Frederick; William J French; C Michael Gibson; Charles V Pollack; Joseph P Ornato; Robert J Zalenski; Jan Penney; Alan J Tiefenbrunn; Philip Greenland Journal: Am J Cardiol Date: 2012-07-27 Impact factor: 2.778
Authors: Choongki Kim; Hyuk-Jae Chang; Iksung Cho; Ji Min Sung; Donghoon Choi; Myung Ho Jeong; Yang Soo Jang Journal: Korean J Intern Med Date: 2013-08-14 Impact factor: 2.884
Authors: Pensée Wu; Kelvin P Jordan; Carolyn A Chew-Graham; Thais Coutinho; Gina P Lundberg; Ki E Park; Lucy C Chappell; Phyo K Myint; Angela H E M Maas; Mamas A Mamas Journal: J Am Heart Assoc Date: 2020-07-29 Impact factor: 5.501